High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
about
Mesothelin-Targeted CARs: Driving T Cells to Solid TumorsComprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.Prognostic significance of TCF21 mRNA expression in patients with lung adenocarcinoma.Mesothelin Immunotherapy for Cancer: Ready for Prime Time?Plasma Mesothelin as a Novel Diagnostic and Prognostic Biomarker in Colorectal Cancer.Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsImmunotherapy for non-small cell lung cancer: current concepts and clinical trials.Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers: A Predictive Multivariate Model.Should anti-mesothelin therapies be explored in lung cancer?Immunotoxin Therapy for Lung Cancer.Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART).Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.Mesothelin-specific Immune Responses Predict Survival of Patients With Brain Metastasis.Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants.Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma.Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer
P2860
Q26778759-E379B6DB-582E-4421-AAA8-D3F64FA7923AQ33688809-D0E1BCCB-C3DC-4394-8140-1A0EA92A75C2Q33700571-EB5B2C5B-271C-487A-B70B-CAFA9911D6A8Q33816551-388A77FB-BC67-487A-B75F-20BB18EF43FAQ33820839-22422992-8BE9-4E33-B919-F548C4F7B822Q33833475-78EEA92D-66BF-442D-98A6-3340CC5D3A77Q36852170-CD17AF07-21CB-481C-80E3-FB90103359B9Q37207143-EBDDCE4D-D43C-47D8-A0E5-02E9330BBB20Q37561979-1FB54C40-7AA1-4D3C-8439-3DE7FE56C4E1Q37684156-920D9A46-0E50-4A85-BF48-B384CFFFD942Q38681083-D74E4543-1C96-466E-977E-98AA967CBF41Q38773361-99D474D9-A7F1-496B-88BA-628DBFE789CDQ38799845-CC0CA5F5-DEF0-413A-920B-981C4DEC8ED6Q39305346-9C55B856-9C41-45A1-8B90-BFF2DBF57C20Q40049272-444A0FF7-23E7-46BB-B9B6-34EB6D0FDA13Q41228566-543A82FF-98E4-419C-91ED-994C869A0E18Q41934574-D14AF3B9-277B-4834-AD44-4BEA1E5E4365Q47153393-9988F269-F8A5-40D2-8886-1D83EC03DC00Q50027827-32B3E0C5-9A14-4DA5-A098-85D6BF459AEEQ55257427-63174BCC-7AF5-4DB9-AA50-339678D42BA7Q58128443-6A971786-E17F-49B9-824F-1F7629312DF9
P2860
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
High mesothelin expression in ...... utations and a poor prognosis.
@ast
High mesothelin expression in ...... utations and a poor prognosis.
@en
type
label
High mesothelin expression in ...... utations and a poor prognosis.
@ast
High mesothelin expression in ...... utations and a poor prognosis.
@en
prefLabel
High mesothelin expression in ...... utations and a poor prognosis.
@ast
High mesothelin expression in ...... utations and a poor prognosis.
@en
P2093
P2860
P356
P1433
P1476
High mesothelin expression in ...... mutations and a poor prognosis
@en
P2093
Anish Thomas
Arun Rajan
Christine Alewine
Giuseppe Giaccone
Ira Pastan
Mark Raffeld
Markku Miettinen
Raffit Hassan
Seth M Steinberg
P2860
P304
11694-11703
P356
10.18632/ONCOTARGET.3429
P407
P577
2015-05-01T00:00:00Z